Update upon efficacy and safety of TNF-α inhibitors

Giuseppe Murdaca, Barbara Maria Colombo, Paola Cagnati, Rossella Gulli, Francesca Span, Francesco Puppo

Research output: Contribution to journalArticlepeer-review


The ongoing progresses in the knowledge of the pathogenic mechanisms of various immune-mediated and inflammatory diseases as well as the availability of innovative biotechnological approaches have led to the development of new drugs that add to conventional treatments. Among these, tumor necrosis factor (TNF)-α inhibitors, that is, infliximab, adalimumab, etanercept, golimumab and certolizumab pegol, are now available for clinical use. This editorial discusses the recent indications of TNF-α inhibitors, the pretreatment considerations, the reported adverse events and, finally, the recommendations for its use in pregnancy.

Original languageEnglish
Pages (from-to)1-5
Number of pages5
JournalExpert Opinion on Drug Safety
Issue number1
Publication statusPublished - Jan 2012


  • Efficacy
  • Immune-mediated diseases
  • Safety
  • TNF-α inhibitors

ASJC Scopus subject areas

  • Pharmacology (medical)


Dive into the research topics of 'Update upon efficacy and safety of TNF-α inhibitors'. Together they form a unique fingerprint.

Cite this